Stock Name: Biosensors
Company Name: BIOSENSORS INT'L GROUP, LTD.
Kim Eng Research in a Jan 30 research report says: "We think that two emerging trends would help sharpen the company's growth prospects. The first is Shandong Weigao taking on a more active role in its capacity as Biosensors' majority shareholder and the second, China's SFDA approval for BioMatrix should be forthcoming.
"Biosensors sees itself morphing from a single-product company to become a medical device platform. To this end, it plans to expand its product offerings, possibly through M&A activities. We believe that this is a necessary step to spur continual growth in the company as well as to diversify its product risks.
"We therefore assign a higher PER of 18x to Biosensors' drug-eluting stent (DES) business to take into account greater growth potential. Target price of $1.80. UPGRADE TO BUY."
Company Name: BIOSENSORS INT'L GROUP, LTD.
| Research House: Kim Eng | Price Call: BUY | Target Price: 1.80 |
Kim Eng Research in a Jan 30 research report says: "We think that two emerging trends would help sharpen the company's growth prospects. The first is Shandong Weigao taking on a more active role in its capacity as Biosensors' majority shareholder and the second, China's SFDA approval for BioMatrix should be forthcoming.
"Biosensors sees itself morphing from a single-product company to become a medical device platform. To this end, it plans to expand its product offerings, possibly through M&A activities. We believe that this is a necessary step to spur continual growth in the company as well as to diversify its product risks.
"We therefore assign a higher PER of 18x to Biosensors' drug-eluting stent (DES) business to take into account greater growth potential. Target price of $1.80. UPGRADE TO BUY."
No comments:
Post a Comment